Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer

Nat Rev Urol. 2023 Jan;20(1):3-4. doi: 10.1038/s41585-022-00671-5.

Authors

Kerem Atalar¹, Prabhakar Rajan^{2

3}

Affiliations

¹ Department of Urology, Barts Health NHS Trust, Whipps Cross University Hospital, London, UK. k.atalar@nhs.net.
² Barts Cancer Institute, Queen Mary University of London, London, UK.
³ Department of Urology, Barts Health NHS Trust, The Royal London Hospital, London, UK.

PMID: 36280769
DOI: 10.1038/s41585-022-00671-5

No abstract available

MeSH terms

Androgen Antagonists / adverse effects
Androgens
Cardiovascular Diseases* / chemically induced
Heart Disease Risk Factors
Humans
Male
Prostatic Neoplasms* / drug therapy
Risk Factors

Substances

Androgen Antagonists
Androgens